STOCKHOLM, January 26 /PRNewswire/ -- Eribis Pharmaceuticals AB - part of the Karolinska Development portfolio - announced today that it has received follow-on financial investment enabling the company to continue its clinical development program. Based on cardio-protective effects, Eribis' candidate drug has the potential to become an important new therapy for treating acute coronary syndrome (ACS) and reperfusion injury (damage to tissue caused when blood supply returns after a period of ischemia), as well as for surgical preconditioning. The new round of investment from Karolinska Development AB will allow Eribis to strengthen the preclinical material.
In studies to date, Eribis' novel peptide therapy has shown excellent Cardio-protective effects in conditions of ACS and reperfusion. Potential benefits of the candidate drug include a decrease in the amount of cardiac tissue damage, an extension of the window of time available for treatment of ischemic conditions and a reduction of cardiovascular complications such as heart failure.
Eribis Pharmaceutical's CEO, Herman Krapf, said, "We are delighted that Karolinska Development continues to show confidence in our development program. This latest round of financing comes after strong preclinical results and means we can now move forward towards the clinical program. Successful development offers significant market potential as there is an urgent need for new and improved therapies in the area of cardio-protection."
About Acute Coronary Syndrome
Cardiovascular disorders are the leading cause of mortality worldwide and remain an area of unmet medical needs. Acute coronary syndrome (ACS) refers to any group of clinical symptoms compatible with acute myocardial ischaemia (chest pain due to insufficient blood supply to the heart muscle that results from coronary artery disease). The consequence of an ACS event is destruction of the heart tissue due to reduced blood flow to the heart. Following recovery from an episode of ACS, patients continue to be at heightened risk of heart attack and stroke.
About Eribis Pharmaceuticals
Eribis Pharmaceuticals is focused on the development of novel drugs for the treatment of cardiovascular disorders, in particular acute myocardial ischemia, as well as surgical preconditioning. The company has unique competence in the development of peptides for pharmacological use. Eribis' novel peptide candidate drug represents a new drug category aimed at meeting the market need for new and improved treatment in the field of cardio-protection.Eribis is a Karolinska Development AB portfolio company.
About Karolinska Development
Karolinska Development manages one of the largest portfolios of life science companies in Europe. Using a unique, highly cost-efficient business model, the management team guides the commercialization of world-class life science innovations, helping to shape the next-generation pharma industry. Since 2003, Karolinska Development has built a portfolio of some 40 companies; among the company's projects 12 compounds are undergoing clinical trials. The portfolio also includes a total of 19 potential first-in-class products.
http://www.karolinskadevelopment.com For more information, please contact: Herman Krapf CEO Herman.email@example.com +46-70-666-50-95
SOURCE Eribis Pharmaceuticals AB